A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 20-2167
More information available at ClinicalTrials.gov: NCT04494425
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers